HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Analysis of different application systems and CT-controlled planning variants in treatment of primary endometrial carcinomas. Is brachytherapy treatment of the entire uterus technically possible?].

AbstractBACKGROUND:
Intracorporal brachytherapy is regarded as the definitive component of treatment for inoperable patients with endometrial carcinoma. Until now the whole uterus has been claimed to represent the target volume independent of individual tumor spread. The purpose of this work is to analyse the correlation between target volume and treated volume using different application- and planning procedures.
PATIENTS AND METHODS:
In a consecutive series of 10 patients with primary irradiated endometrial carcinoma we analyzed the correlation between target volume and treated volume using either standard 1-channel applicators or individual Heyman-applicators. Application of the ovoids was followed by a planning CT scan for all patients. Based on this, target volume (uterus volume) was estimated on a 3D-planning system. According to the measurable length of the uterus cavity we determined the corresponding standard 1-channel applicator and calculated the respectively treated volume. Estimating the advantages of an optimized treatment planning strategy for individual Heyman-applications were compared the treated volumes, which result from a standardized and optimized treatment planning procedure.
RESULTS:
The mean uterus volume was 180 cm3 (range 57 to 316 cm3). Asymmetric uterus configurations with longitudinal or sagittal side differences exceeding 1 cm were found in 40% of the cases. Using standard 1-channel applicators on average 47% (range 25 to 89%) of the uterus volume were enclosed by the treated volume compared to 70% for Heyman-applications. Differentiating these individual applications according to the variable treatment modality values of mean 66% (range 36 to 110%) for the standardized and 73% (range 48 to 95%) for the optimized treatment planning strategy were found. Moreover optimized planning modalities led to an improved coverage of the target volume in 5 out of 10 cases with an increase in volume of 20% on average (range 11 to 32%). In 3 cases changes of less than 5% were noticed (no improvement). In order to protect organs at risk treated volume had to be decreased in 2 cases for 19% and 40% respectively.
CONCLUSIONS:
Intracavitary brachytherapy of primary endometrial carcinoma was improved by individualized application- and planning procedures, which led to better adaptations of the treated volumes to the target volumes. Nevertheless a complete coverage--corresponding to the primary intent--was not possible. Individualized and optimized brachy-therapy must be performed according to the individual tumor spread and uterus configuration. Therefore, different applicators are required.
AuthorsM Mock, T Knocke, C Fellner, R Pötter
JournalStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (Strahlenther Onkol) Vol. 174 Issue 6 Pg. 320-8 (Jun 1998) ISSN: 0179-7158 [Print] Germany
Vernacular TitleAnalyse unterschiedlicher Applikationsformen und CT-gestützter Planungsvarianten in der Behandlung primärer Endometriumkarzinome. Ist die brachytherapeutische Erfassung des gesamten Uterus technisch möglich?
PMID9645214 (Publication Type: English Abstract, Journal Article)
Topics
  • Adenocarcinoma (pathology, radiotherapy)
  • Brachytherapy (instrumentation)
  • Endometrial Neoplasms (pathology, radiotherapy)
  • Endometrium (pathology, radiation effects)
  • Equipment Design
  • Female
  • Humans
  • Image Processing, Computer-Assisted (instrumentation)
  • Neoplasm Staging
  • Organ Size (radiation effects)
  • Radiation Dosage
  • Radiotherapy Planning, Computer-Assisted (instrumentation)
  • Tomography, X-Ray Computed (instrumentation)
  • Uterus (pathology, radiation effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: